Perjeta Panel Review Could Pave Way For Neoadjuvant Approvals
This article was originally published in The Pink Sheet Daily
The September advisory committee review of Roche’s sBLA for Perjeta will be the first test of the agency’s guidance on using accelerated approval for neoadjuvant breast cancer.
You may also be interested in...
Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.
Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.
Genentech pledges to make new HER2-positive drug Perjeta (pertuzumab) available in the U.S. in two weeks, addresses FDA concerns about production issues and a potential shortage. Firm is already moving forward with plans for integrating Perjeta into its breast cancer portfolio, including combination with antibody-drug conjugate T-DM1.